1. Telugu R.B., Chowhan A.K., Rukmangadha N., Patnayak R., Phaneendra B.V., Prasad B.C., Reddy M.K. Human epidermal growth factor receptor 2/neu protein expression in meningiomas: An immunohistochemical study. J. Neurosci. Rural Pract. 2016; 7 (4): 526–531. doi: 10.4103/0976-3147.188640
2. Zavyalova M., Vtorushin S., Krakhmal N., Savelieva O., Tashireva L., Kaigorodova E., Perelmuter V., Telegina N., Denisov E., Bragina O., Slonimskaya E., Choynzonov E. Clinicopathological features of nonspecific invasive breast cancer according to its molecular subtypes. Exp. Oncol. 2016; 38 (2): 122–127. doi: 10.31768/2312-8852.2016.38(2):122-127
3. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E.Jr., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005; 353: 1673–1684. doi: 10.1056/NEJMoa052122
4. Orlando L., Viale G., Bria E., Lutrino E.S., Sperduti I., Carbognin L., Schiavone P., Quaranta A., Fedele P., Caliolo C., Calvani N., Criscuolo M., Cinieri S. Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment. Breast. 2016; 30: 151–155. doi: 10.1016/j.breast.2016.09.015
5. Zahid M., Khan S., Khan R., Shireen A., Fatima S. Detection of Her2/neu gene amplification by fluorescence in situ hybridization technique. Pathology. 2016; 48 (1): 163–170. doi: 10.1016/j.pathol.2015.12.447
6. Чернов В.И., Брагина О.Д., Зельчан Р.В., Медведева А.А., Синилкин И.Г., Ларькина М.С., Стасюк Е.С., Нестеров Е.А., Скуридин В.С. Меченые аналоги соматостатина в тераностике нейроэндокринных опухолей. Медицинская радиология и радиационная безопасность. 2017; 62 (3): 42–49.
Chernov V.I., Bragina O.D., Zel’chan R.V., Medvedeva A.A., Sinilkin I.G., Larkina M.S., Stasyuk E.S., Nesterov E.A., Skuridin V.S. Labeled somatostatin analogues in theranostics of neuroendocrine tumors. Meditsinskaya radiologiya i radiatsionnaya bezopasnost’ = Medical Radiology and Radiation Safety. 2017; 62 (3): 42–49. [In Russian].
7. Чернов В.И., Медведева А.А., Синилкин И.Г., Зельчан Р.В., Брагина О.Д., Чойнзонов Е.Л. Ядерная медицина в диагностике и адресной терапии злокачественных новообразований. Бюл. сиб. мед. 2018; 17 (1): 220–231. doi: 1682-0363-2018-1-220-231
Chernov V.I., Medvedeva A.A., Sinilkin I.G., Zelchan R.V., Bragina O.D., Choinzonov E.L. Nuclear medicine as a tool for diagnosis and targeted cancer therapy. Byulleten’ sibirskoy meditsiny = Bulletin of Siberian Medicine. 2017; 16 (3): 25–33. [In Russian]. doi: 1682-0363-2018-1-220-231
8. Chernov V.I., Sinilkin I.G., Zelchan R.V., Medvedeva A.A., Lyapunov A.Yu., Bragina O.D., Varlamova N.V., Skuridin V.S. Experimental study of 99mTc-aluminum oxide use for sentinel lymph nodes detection. Physics of Cancer: Interdisciplinary Problems and Clinical Applications, PC 2016: Proceedings of the International conference on physics of cancer: interdisciplinary problems and clinical applications. 2016; 1760: 020012. doi: 10.1063/1.4960231
9. Garousi J., Honarvar H., Andersson K.G., Mitran B., Orlova A., Buijs J., Löfblom J., Frejd F.Y., Tolmachev V. Comparative evaluation of affibody molecules for radionuclide imaging of in vivo expression of carbonic anhydrase IX. Mol Pharm. 2016; 13 (11): 3676–3687. doi: 10.1021/acs.molpharmaceut.6b00502
10. Брагина О.Д., Чернов В.И., Зельчан Р.В., Синилкин И.Г., Медведева А.А., Ларькина М.С. Альтернативные каркасные белки в радионуклидной диагностике злокачественных образований. Бюл. сиб. мед. 2019; 18 (3): 125–133. doi: 1682-0363-2019-3-125-133
Bragina O.D., Chernov V.I., Zelchan R.V., Sinilkin I.G., Medvedeva A.A., Larkina M.S. Alternative scaffolds in radionuclide diagnosis of malignancies. Byulleten’ sibirskoy meditsiny = Bulletin of Siberian medicine. 2019; 18 (3): 125–133. [In Russian]. doi: 1682-0363-2019-3-125-133
11. Nicholes N., Date A., Beaujean P., Hauk P., Kanwar M., Ostermeier M. Modular protein switches derived from antibody mimetic proteins. Protein Eng. Des. Sel. 2016; 29: 77–85. doi: 10.1093/protein/gzv062
12. Tolmachev V., Orlova A., Andersson K. Methods for radiolabelling of monoclonal antibodies. Methods Mol. Biol. 2014; 1060: 309–330. doi: 10.1007/978-1-62703-586-6_16
13. Stumpp M.T., Binz H.K., Amstutz P. DARPins: A new generation of protein therapeutics. Drug Discov. Today. 2008; 13 (15): 695–701. doi: 10.1016/j.drudis.2008.04.013
14. Binz H.K., Stumpp M.T., Forrer P., Amstutz P., Pluckthun A. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J. Mol. Biol. 2003; 332: 489–503. doi:10.1016/s0022-2836(03)00896-9
15. Goldstein R., Sosabowski J., Livanos M., Leyton J., Vigor K., Bhavsar G., Nagy-Davidescu G., Rashid M., Miranda E., Yeung J., Tolner B., Plückthun A., Mather S., Meyer T., Chester K. Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging. Eur. J. Nucl. Med. Mol. Imaging. 2015; 42 (2): 288–301. doi: 10.1007/s00259-014-2940-2
16. Boersma Y.L., Pluckthun A. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr. Opin. Biotechnol. 2011; 22: 849–857. doi: 10.1016/j.copbio.2011.06.004
17. Hanenberg M., McAfoose J., Kulic L., Welt T., Wirth F., Parizek P., Strobel L., Cattepoel S., Späni C., Derungs R., Maier M., Plückthun A., Nitsch R.M. Amyloid-β peptide-specific DARPins as a novel class of potential therapeutics for Alzheimer disease. J. Biol. Chem. 2014; 26: 27080–27089. doi: 10.1074/jbc.M114.564013
18. Hausammann S., Vogel M., Kremer J.A., Lacroix-Desmazes S., Stadler B.M., Horn M.P. Designed ankyrin repeat proteins: a new approach to mimic complex antigens for diagnostic purposes? PLoS One. 2013; 8: 1–9. doi: 10.1371/journal.pone.0060688
19. Houlihan G., Gatti-Lafranconi P., Lowe D., Hollfelder F. Directed evolution of anti-HER2 DARPins by SNAP display reveals stability/function trade-offs in the selection process. Protein Eng. Des. Sel. 2015; 28 (9): 269–279. doi: 10.1093/protein/gzv029
20. Kramer L., Renko M., Završnik J., Turk D., Seeger M.A., Vasiljeva O., Grütter M.G., Turk V., Turk B. Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin. Theranostics. 2017; 8: 2806–2821. doi: 10.7150/thno.19081
21. Moody P., Chudasama V., Nathani R.I., Maruani A., Martin S., Smith M.B., Caddick S. A rapid, site-selective and efficient route to the dual modification of DARPins. Chem. Commun. (Camb.). 2014: 50 (38): 4898–4900. doi: 10.1039/c4cc00053f
22. Plückthun A. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu. Rev. Pharmacol. Toxicol. 2015; 55: 489–511. doi: 10.1146/annurev-pharmtox-010611-134654
23. Tamaskovic R., Simon M., Stefan N., Schwill M., Plückthun A. Designed ankyrin repeat proteins (DARPins) from research to therapy. Methods Enzymol. 2012; 503: 101–134. doi: 10.1146/annurev-pharmtox-010611-134654
24. Vorobyeva A., Schulga A., Konovalova E., Güler R., Löfblom J., Sandström M., Garousi J., Chernov V., Bragina O., Orlova A., Tolmachev V., Deyev S.M. Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPinG3. Sci. Rep. 2019: 9 (1); 9405. doi: 10.1038/s41598-019-45795-8
25. Брагина О.Д., Ларькина М.С., Стасюк Е.С., Чернов В.И., Юсубов М.С., Скуридин В.С., Деев С.М., Зельчан Р.В., Булдаков М.А., Подрезова Е.В., Белоусов М.В. Разработка высокоспецифичного радиохимического соединения на основе меченных 99mTc рекомбинантных адресных молекул для визуализации клеток с гиперэкспрессией Her2/neu. Бюл. сиб. мед. 2017; 16 (3): 25–33. doi: 1682-0363-2017-3-25-33
Bragina O.D., Larkina M.S., Stasyuk E.S., Chernov V.I., Yusubov M.S., Skuridin V.S., Deyev S.M., Zel’chan R.V., Buldakov M.A., Podrezova E.V., Belousov M.V. The development of a highly specific radiochemical compound based on labeled 99mtc recombinant molecules for targeted imaging of cells with the overexpression of Her2/neu. Byulleten’ sibirskoy meditsiny = Bulletin of Siberian Medicine. 2017; 16 (3): 25–33. [In Russian]. doi: 1682-0363-2017-3-25-33
26. Vorobyeva A., Bragina O., Altai M., Mitran B., Orlova A., Shulga A., Proshkina G., Chernov V., Tolmachev V., Deyev S. Comparative evaluation of radioiodine and technetium-labeled DARPin 9_29 for radionuclide molecular imaging of HER2 expression in malignant tumors. Contrast Media Mol. Imaging. 2018; 2018: 6930425. doi: 10.1155/2018/6930425
27. Sandberg D., Tolmachev V., Velikyan I., Olofsson H., Wennborg A., Feldwisch J., Carlsson J., Lindman H., Sörensen J. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the affibody molecule ABY-025 with PET and SPECT. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (8): 1337–1346. doi: 10.1007/s00259-017-3650-3